{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T01:42:11Z","timestamp":1792460531123,"version":"4.5.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,27]],"date-time":"2024-07-27T00:00:00Z","timestamp":1722038400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy - Nucleic Acids"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.omtn.2024.102289","type":"journal-article","created":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T02:18:31Z","timestamp":1722392311000},"page":"102289","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["DNA\/RNA heteroduplex technology with cationic oligopeptide reduces class-related adverse effects of nucleic acid drugs"],"prefix":"10.1016","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0344-251X","authenticated-orcid":false,"given":"Masahiro","family":"Ohara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Nagata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rintaro Iwata","family":"Hara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kie","family":"Yoshida-Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nozomi","family":"Toide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunori","family":"Takagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoya","family":"Takenaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Nakakariya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Miyata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuko","family":"Toh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Wada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6490-3263","authenticated-orcid":false,"given":"Takanori","family":"Yokota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtn.2024.102289_bib1","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/S0016-5085(98)70418-4","article-title":"WR. A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease","volume":"114","author":"Yacyshyn","year":"1998","journal-title":"Gastroenterology"},{"key":"10.1016\/j.omtn.2024.102289_bib2","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0300-483X(97)03661-5","article-title":"Evaluation of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide, in a four-week study in cynomolgus monkeys","volume":"120","author":"Henry","year":"1997","journal-title":"Toxicology"},{"key":"10.1016\/j.omtn.2024.102289_bib3","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1089\/ard.1994.4.201","article-title":"Complement activation and hemodynamic changes following intravenous administration of phosphorothioate oligonucleotides in the monkey","volume":"4","author":"Galbraith","year":"1994","journal-title":"Antisense Res. Dev."},{"key":"10.1016\/j.omtn.2024.102289_bib4","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1089\/nat.2016.0650","article-title":"The effects of 2'-O-methoxyethyl containing antisense oligonucleotides on platelets in human clinical trials","volume":"27","author":"Crooke","year":"2017","journal-title":"Nucleic Acid Therapeut."},{"key":"10.1016\/j.omtn.2024.102289_bib5","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1177\/0192623314551840","article-title":"Antisense oligonucleotide therapies: the promise and the challenges from a toxicologic pathologist's perspective","volume":"43","author":"Frazier","year":"2015","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.omtn.2024.102289_bib6","doi-asserted-by":"crossref","first-page":"7969","DOI":"10.1038\/ncomms8969","article-title":"DNA\/RNA heteroduplex oligonucleotide for highly efficient gene silencing","volume":"6","author":"Nishina","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtn.2024.102289_bib7","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1038\/s41587-021-00972-x","article-title":"Cholesterol-functionalized DNA\/RNA heteroduplexes cross the blood-brain barrier and knock down genes in the rodent CNS","volume":"39","author":"Nagata","year":"2021","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omtn.2024.102289_bib8","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1016\/j.omtn.2020.11.022","article-title":"Separation-related rapid nuclear transport of DNA\/RNA heteroduplex oligonucleotide: unveiling distinctive intracellular trafficking","volume":"23","author":"Ono","year":"2021","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2024.102289_bib9","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus sham control in infantile-onset spinal muscular atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omtn.2024.102289_bib10","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S1474-4422(13)70061-9","article-title":"An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study","volume":"12","author":"Miller","year":"2013","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.omtn.2024.102289_bib11","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1056\/NEJMoa1900907","article-title":"Targeting huntingtin expression in patients with Huntington\u2019s disease","volume":"380","author":"Tabrizi","year":"2019","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omtn.2024.102289_bib12","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aag0481","article-title":"Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy","volume":"9","author":"DeVos","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omtn.2024.102289_bib13","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1186\/s12967-020-02461-2","article-title":"Convective forces increase rostral delivery of intrathecal radiotracers and antisense oligonucleotides in the cynomolgus monkey nervous system","volume":"18","author":"Sullivan","year":"2020","journal-title":"J.\u00a0Transl. Med."},{"key":"10.1016\/j.omtn.2024.102289_bib14","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.129240","article-title":"Brain pharmacology of intrathecal antisense oligonucleotides revealed through multimodal imaging","volume":"4","author":"Mazur","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.omtn.2024.102289_bib15","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1016\/j.bmc.2013.01.053","article-title":"Synthesis and properties of cationic oligopeptides with different side chain lengths that bind to RNA duplexes","volume":"21","author":"Maeda","year":"2013","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.omtn.2024.102289_bib16","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1080\/15257770.2018.1543890","article-title":"Artificial cationic peptides that increase nuclease resistance of siRNA without disturbing RNAi activity","volume":"38","author":"Maeda","year":"2019","journal-title":"Nucleos Nucleot. Nucleic Acids"},{"key":"10.1016\/j.omtn.2024.102289_bib17","doi-asserted-by":"crossref","first-page":"4323","DOI":"10.1038\/s41598-018-22161-8","article-title":"Artificial cationic oligosaccharides for heteroduplex oligonucleotide-type drugs","volume":"8","author":"Hara","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omtn.2024.102289_bib18","article-title":"Correction: Enhancement in RNase H activity of a DNA\/RNA hybrid duplex using artificial cationic oligopeptides","volume":"54","author":"Hara","year":"2018","journal-title":"Chem. Commun."},{"key":"10.1016\/j.omtn.2024.102289_bib19","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.biomaterials.2018.01.042","article-title":"Dual-responsive polyplexes with enhanced disassembly and endosomal escape for efficient delivery of siRNA","volume":"162","author":"Zhu","year":"2018","journal-title":"Biomaterials"},{"key":"10.1016\/j.omtn.2024.102289_bib20","doi-asserted-by":"crossref","first-page":"6844","DOI":"10.1021\/acs.chemrev.8b00199","article-title":"Block Copolymer Micelles in Nanomedicine Applications","volume":"118","author":"Cabral","year":"2018","journal-title":"Chem. Rev."},{"key":"10.1016\/j.omtn.2024.102289_bib21","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1038\/s41467-019-09856-w","article-title":"In\u00a0vivo rendezvous of small nucleic acid drugs with charge-matched block catiomers to target cancers","volume":"10","author":"Watanabe","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtn.2024.102289_bib22","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jconrel.2006.04.014","article-title":"Toxicity of cationic lipids and cationic polymers in gene delivery","volume":"114","author":"Lv","year":"2006","journal-title":"J.\u00a0Contr. Release"},{"key":"10.1016\/j.omtn.2024.102289_bib23","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1089\/108729001300338681","article-title":"Toxicity and toxicokinetics of a phosphorothioate oligonucleotide against the c-myc oncogene in cynomolgus monkeys","volume":"11","author":"Webb","year":"2001","journal-title":"Antisense Nucleic Acid Drug Dev."},{"key":"10.1016\/j.omtn.2024.102289_bib24","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1089\/oli.1.1997.7.503","article-title":"Inhibition of coagulation by a phosphorothioate oligonucleotide","volume":"7","author":"Henry","year":"1997","journal-title":"Antisense Nucleic Acid Drug Dev."},{"key":"10.1016\/j.omtn.2024.102289_bib25","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1182\/blood.V92.5.1617","article-title":"Phosphorothioate oligonucleotides inhibit the intrinsic tenase complex","volume":"92","author":"Sheehan","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.omtn.2024.102289_bib26","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1089\/nat.2014.0491","article-title":"Mechanism of alternative complement pathway dysregulation by a phosphorothioate oligonucleotide in monkey and human serum","volume":"24","author":"Henry","year":"2014","journal-title":"Nucleic Acid Therapeut."},{"key":"10.1016\/j.omtn.2024.102289_bib27","doi-asserted-by":"crossref","first-page":"3558","DOI":"10.1172\/JCI99081","article-title":"Antisense oligonucleotides extend survival and reverse decrement in muscle response in ALS models","volume":"128","author":"McCampbell","year":"2018","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.omtn.2024.102289_bib28","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/bmb.20649","article-title":"Using electrophoretic mobility shift assays to measure equilibrium dissociation constants: GAL4-p53 binding DNA as a model system","volume":"40","author":"Heffler","year":"2012","journal-title":"Biochem. Mol. Biol. Educ."},{"key":"10.1016\/j.omtn.2024.102289_bib29","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1089\/nat.2015.0593","article-title":"Considerations for the Characterization and Interpretation of Results Related to Alternative Complement Activation in Monkeys Associated with Oligonucleotide-Based Therapeutics","volume":"26","author":"Henry","year":"2016","journal-title":"Nucleic Acid Therapeut."},{"key":"10.1016\/j.omtn.2024.102289_bib30","article-title":"Waking inactivity as a welfare indicator in laboratory mice: investigating postures, facial expressions and depression-like states","volume":"9","author":"MacLellan","year":"2022","journal-title":"R.\u00a0Soc. Open Sci."},{"key":"10.1016\/j.omtn.2024.102289_bib31","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/nmeth.1455","article-title":"Coding of facial expressions of pain in the laboratory mouse","volume":"7","author":"Langford","year":"2010","journal-title":"Nat. Methods"},{"key":"10.1016\/j.omtn.2024.102289_bib32","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1093\/nar\/gky1260","article-title":"Characterization of the interactions of chemically-modified therapeutic nucleic acids with plasma proteins using a fluorescence polarization assay","volume":"47","author":"Gaus","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2024.102289_bib33","doi-asserted-by":"crossref","first-page":"5235","DOI":"10.1093\/nar\/gkaa299","article-title":"Phosphorothioate modified oligonucleotide-protein interactions","volume":"48","author":"Crooke","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2024.102289_bib34","doi-asserted-by":"crossref","first-page":"663","DOI":"10.2174\/1389450115666140321100304","article-title":"Phosphorothioate oligonucleotides: effectiveness and toxicity","volume":"15","author":"Iannitti","year":"2014","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.omtn.2024.102289_bib35","first-page":"6045","article-title":"Conjugation of hydrophobic moieties enhances potency of antisense oligonucleotides in the muscle of rodents and non-human primates","volume":"47","author":"\u00d8stergaard","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2024.102289_bib36","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jconrel.2016.02.007","article-title":"Evaluation of the effects of chemically different linkers on hepatic accumulations, cell tropism and gene silencing ability of cholesterol-conjugated antisense oligonucleotides","volume":"226","author":"Wada","year":"2016","journal-title":"J.\u00a0Contr. Release"},{"key":"10.1016\/j.omtn.2024.102289_bib37","doi-asserted-by":"crossref","first-page":"5422","DOI":"10.4049\/jimmunol.157.12.5422","article-title":"Identification of a heparin binding domain in the seventh short consensus repeat of complement factor H","volume":"157","author":"Blackmore","year":"1996","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.omtn.2024.102289_bib38","doi-asserted-by":"crossref","first-page":"3342","DOI":"10.4049\/jimmunol.160.7.3342","article-title":"Identification of the second heparin-binding domain in human complement factor H","volume":"160","author":"Blackmore","year":"1998","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.omtn.2024.102289_bib39","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.drudis.2017.01.013","article-title":"Safety of antisense oligonucleotide and siRNA-based therapeutics","volume":"22","author":"Chi","year":"2017","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.omtn.2024.102289_bib40","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0187574","article-title":"Assessing single-stranded oligonucleotide drug-induced effects in\u00a0vitro reveals key risk factors for thrombocytopenia","volume":"12","author":"Sewing","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.omtn.2024.102289_bib41","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1093\/toxsci\/kfy119","article-title":"Investigation into the Mechanism(s) That Leads to Platelet Decreases in Cynomolgus Monkeys During Administration of ISIS 104838, a 2'-MOE-Modified Antisense Oligonucleotide","volume":"164","author":"Narayanan","year":"2018","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.omtn.2024.102289_bib42","doi-asserted-by":"crossref","first-page":"519","DOI":"10.3324\/haematol.2020.260059","article-title":"Sequence-specific 2'-O-methoxyethyl antisense oligonucleotides activate human platelets through glycoprotein VI, triggering formation of platelet-leukocyte aggregates","volume":"107","author":"Slingsby","year":"2022","journal-title":"Haematologica"},{"key":"10.1016\/j.omtn.2024.102289_bib43","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1182\/blood-2013-01-478966","article-title":"Complex formation with nucleic acids and aptamers alters the antigenic properties of platelet factor 4","volume":"122","author":"Jaax","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.omtn.2024.102289_bib44","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/bcp.12961","article-title":"Injection site reactions after subcutaneous oligonucleotide therapy","volume":"82","author":"van Meer","year":"2016","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.omtn.2024.102289_bib45","first-page":"614","article-title":"Administration of substances to laboratory animals: equipment considerations, vehicle selection, and solute preparation","volume":"50","author":"Turner","year":"2011","journal-title":"J.\u00a0Am. Assoc. Lab. Anim. Sci."},{"key":"10.1016\/j.omtn.2024.102289_bib46","doi-asserted-by":"crossref","first-page":"5465","DOI":"10.1093\/nar\/gkz247","article-title":"Site-specific replacement of phosphorothioate with alkyl phosphonate linkages enhances the therapeutic profile of gapmer ASOs by modulating interactions with cellular proteins","volume":"47","author":"Migawa","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2024.102289_bib47","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1038\/s41587-019-0106-2","article-title":"Chemical modification of PS-ASO therapeutics reduces cellular protein-binding and improves the therapeutic index","volume":"37","author":"Shen","year":"2019","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omtn.2024.102289_bib48","doi-asserted-by":"crossref","first-page":"9026","DOI":"10.1093\/nar\/gkab718","article-title":"Towards next generation antisense oligonucleotides: mesylphosphoramidate modification improves therapeutic index and duration of effect of gapmer antisense oligonucleotides","volume":"49","author":"Anderson","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2024.102289_bib49","doi-asserted-by":"crossref","DOI":"10.1002\/adma.201903637","article-title":"Rekindling RNAi Therapy: Materials Design Requirements for In\u00a0Vivo siRNA Delivery","volume":"31","author":"Kim","year":"2019","journal-title":"Adv. Mater."},{"key":"10.1016\/j.omtn.2024.102289_bib50","doi-asserted-by":"crossref","first-page":"3754","DOI":"10.1021\/acsnano.8b07858","article-title":"Lipid-Based DNA Therapeutics: Hallmarks of Non-Viral Gene Delivery","volume":"13","author":"Buck","year":"2019","journal-title":"ACS Nano"}],"container-title":["Molecular Therapy - Nucleic Acids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253124001768?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253124001768?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,2]],"date-time":"2024-11-02T06:36:46Z","timestamp":1730529406000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2162253124001768"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":50,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S2162253124001768"],"URL":"https:\/\/doi.org\/10.1016\/j.omtn.2024.102289","relation":{},"ISSN":["2162-2531"],"issn-type":[{"value":"2162-2531","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"DNA\/RNA heteroduplex technology with cationic oligopeptide reduces class-related adverse effects of nucleic acid drugs","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy - Nucleic Acids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtn.2024.102289","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"102289"}}